WealthPlan Investment Management LLC Sells 1,157 Shares of AstraZeneca PLC (NASDAQ:AZN)

WealthPlan Investment Management LLC cut its stake in AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,398 shares of the company’s stock after selling 1,157 shares during the quarter. WealthPlan Investment Management LLC’s holdings in AstraZeneca were worth $6,575,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Harbour Investments Inc. grew its stake in shares of AstraZeneca by 1.9% in the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after acquiring an additional 160 shares during the period. Nations Financial Group Inc. IA ADV grew its stake in shares of AstraZeneca by 5.2% in the third quarter. Nations Financial Group Inc. IA ADV now owns 5,368 shares of the company’s stock worth $418,000 after acquiring an additional 267 shares during the period. Venturi Wealth Management LLC grew its stake in shares of AstraZeneca by 13.0% in the third quarter. Venturi Wealth Management LLC now owns 25,796 shares of the company’s stock worth $2,010,000 after acquiring an additional 2,968 shares during the period. Addison Advisors LLC boosted its holdings in shares of AstraZeneca by 11.9% in the third quarter. Addison Advisors LLC now owns 1,743 shares of the company’s stock worth $136,000 after buying an additional 186 shares during the last quarter. Finally, Catalytic Wealth RIA LLC boosted its holdings in shares of AstraZeneca by 7.0% in the third quarter. Catalytic Wealth RIA LLC now owns 29,008 shares of the company’s stock worth $2,260,000 after buying an additional 1,908 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Trading Up 0.5 %

Shares of AZN opened at $64.79 on Tuesday. The company’s fifty day moving average is $76.61 and its 200 day moving average is $78.54. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The stock has a market capitalization of $200.89 billion, a PE ratio of 31.30, a P/E/G ratio of 1.19 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen raised their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.